T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
Open Access
- 10 September 2024
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 108, 105317
Abstract
No abstract availableKeywords
Funding Information
- Norwegian Institute of Public Health
- Akershus Universitetssykehus
- South-Eastern Norway Regional Health Authority
- Diakonhjemmet University College and Hospital
- Norges Forskningsråd
- Coalition for Epidemic Preparedness Innovations
This publication has 37 references indexed in Scilit:
- Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated PatientsJournal of Crohn's and Colitis, 2021
- Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273JAMA, 2021
- Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patientsBMC Infectious Diseases, 2021
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDGut, 2021
- Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximabGut, 2021
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel DiseasesGastroenterology, 2018
- COMPASS identifies T-cell subsets correlated with clinical outcomesNature Biotechnology, 2015
- TNF-α Antagonists and ImmunizationCurrent Infectious Disease Reports, 2011
- T-cell quality in memory and protection: implications for vaccine designNature Reviews Immunology, 2008
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008